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Background: One hallmark of Alzheimer disease is microglial activation. Therapeutic approaches for this
neurodegenerative disease include the modulation of microglial cells. α1-antitrypsin (A1AT) has been shown
to exert anti-inflammatory effects on macrophages and lung epithelial cells and an inhibition of calpain activity
in neutrophil granulocytes. Nothing is known about the effect of A1AT on microglial-mediated neuroinflammation.
Our aim was to investigate the effect of A1AT on amyloid-β (Aβ)- and LPS-treated microglial cells in vitro with respect
to cytokine production, stress pathways, cell viability, phagocytotic abilities and the underlying mechanisms.
Methods: Primary microglial cells were isolated from Swiss Webster mouse embryos on embryonic day 13.5. Cytokines
in the supernatants of treated primary microglial cells were analyzed with ELISAs, and accumulated nitrite was detected
with Griess reagents. Intracellular stress pathways were investigated in cell lysates using western blotting. Intracellular
calcium levels were detected in BV-2 microglial cells loaded with the Ca2+-sensitive (fluorescent) dye Fluo-4. Calpain
activity in primary microglial cells was assessed by using a calpain activity assay. Cell viability of Aβ-treated microglial
cells was analyzed using MTT assay. Phagocytosis of Aβ was evaluated with western blot analysis.
Results: Upon co-administration, A1AT reduced pro-inflammatory mediators induced by LPS or Aβ. Interestingly,
we detected a reduction in calpain activity and in the concentration of intracellular calcium that might mediate
the anti-inflammatory effects of A1AT. Inhibition of the classic activation pathways, such as phosphorylation
of mitogen-activated protein kinases or activation of protein kinase A were excluded as a mechanism of A1AT-mediated
effects. In addition, A1AT increased the viability of Aβ-treated microglial cells and reduced Aβ phagocytosis.
Conclusions: We provide evidence on the mechanism of action of A1AT on microglial-mediated neuroinflammation
in vitro. Our in vitro data indicate that A1AT treatment modulates microglial cells in inflammatory conditions and that this
modulation is due to an inhibition of calpain activity and intracellular calcium levels. The underlying mechanisms of the
effects observed here are promising for future therapeutic strategies and should thus be further pursued in transgenic
mouse models of Alzheimer disease.
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Alzheimer disease (AD) is the most common neurode-
generative disease leading to the loss of cholinergic neu-
rons and their associated neuronal connections in the
human brain. Pathological hallmarks are the extracellu-
lar formation of amyloid-β (Aβ) plaques and the intra-
cellular formation of neurofibrillary tangles, composed
of hyperphosphorylated tau-protein [1]. Besides its tox-
icity to neurons, Aβ activates microglial cells via differ-
ent receptors expressed on the cell surface, such as
toll-like receptors (TLR) [2]. Intracellular receptor sig-
nalling involves the classical mitogen-activated protein
kinase (MAPK) pathways resulting in the nuclear trans-
location of nuclear factor κB (NFκB) [3] but also activa-
tion of cAMP/protein kinase A (PKA)/phosphorylated
cAMP response element binding protein (CREB) [4].
Upon activation, microglial cells express and secrete
pro-inflammatory factors, thereby generating an even
more neurotoxic milieu [5]. The concentration of intra-
cellular calcium also seems to play a role in the control of
pro-inflammatory mediator release [6], and modulation of
intracellular calcium levels can reduce the secretion of
pro-inflammatory factors [7]. On the other hand, micro-
glial cells also show neuroprotective effects through the
uptake and degradation of toxic Aβ oligomers [8].
One therapeutic approach for AD is to modify neuro-
inflammation towards an activation state that is charac-
terized by reduced production of pro-inflammatory
mediators and increased Aβ clearance [9,10]. Recently, a
new anti-inflammatory role for α1-antitrypsin (A1AT)
has been described for activated monocytes as well as
for lung endothelial cells [11,12]. The serine protease in-
hibitory activity mediated by A1AT protein is well ac-
knowledged for its essential role in the degradation of
neutrophil elastase in the lung [13]. A1AT proteins are
also known for their inflammatory properties as acute
phase proteins being produced in large amounts under
inflammatory conditions [14]. Patients suffering from in-
born A1AT deficiency are predisposed to lung diseases
and to liver cirrhosis, mainly attributed to an accumula-
tion of misfolded A1AT proteins [15]. As a therapy for
inborn A1AT deficiency, substitution with pooled hu-
man A1AT is available. A1AT has also been shown to
reduce calpain activity in neutrophil granulocytes [16].
Calpain, a key enzyme in the progress of neurodegenera-
tive pathology, is activated by elevated intracellular cal-
cium levels and it is strongly associated with endoplasmic
reticulum stress and apoptosis [17]. In postmortem brains
of AD patients, overactivation of calpain can be detected
[18]. Recently, it was demonstrated that calpain activity is
also involved in the activation of immune cells in a colitis
mouse model [19].
In the present study, therefore, the effect of A1AT on
microglial-mediated neuroinflammation and Aβ toxicitywas investigated in murine primary microglial cells and
the rodent microglial cell line BV-2.
Methods
All chemicals were obtained from Sigma-Aldrich, St. Louis,
MO, USA, unless otherwise indicated.
Reagents and antibodies
Prolastin (Grifols, Barcelona, Spain, for more information
see http://www.grifols-pi.info/inserts/Prolastin-C.pdf) was
used as a source for A1AT. Prolastin (1 g) was solubilized
with 40 ml ultrapure water, aliquoted and stored at -80°C
until use.
To obtain Aβ oligomer-enriched preparations, 1 mg
Aβ1-42 (Bachem, Bubendorf, Switzerland) was dissolved in
10% ammonia, aliquoted, freeze dried and stored at -80°C.
Before use, Aβ1-42 aliquots were dissolved in sterile water
(1 mg/ml), and then 100 mM Tris and 50 mM NaCl were
added to obtain a 58 μM solution. A magnetic stirrer was
added and the Aβ solution was stirred for 48 hours at
1,400 rpm at room temperature.
Antibodies against the following proteins were used:
phosphorylated (phospho)-p38, phospho-p44/42, phospho-
JNK (c-Jun N-terminal kinase)/SAPK (stress-activated
protein kinase), phospho-CREB (all Cell Signaling,
Danvers, MA, USA), Aβ (clone 6E10, Covance, Princeton,
NJ, USA), A1AT, Vinculin, glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) (Novus Biologicals, Littleton, CO,
USA) and horseradish peroxidase-conjugated secondary
antibody goat anti-mouse, goat anti-rabbit (both Cell
Signaling, Danvers, MA, USA) and donkey anti-goat
(Santa Cruz Biotechnology, Dallas, TX, USA).
Cells
Primary microglia cells were derived from Swiss Webster
mouse embryos on embryonic day 13.5. All experimental
protocols were approved by the office of the district
president and the Institutional Animal Care and Use
Committee of the University of Marburg. The study re-
ceived institutional review board and experiments were
carried out in accordance with EU Directive 1020/63/EU
on the protection of animals used for scientific purposes.
The procedure has been described in detail by Roettger
et al. [20]. Briefly, mice were sacrificed, embryos were
removed and mesencephalons were dissected and col-
lected in Leibovitz L-15 media (PAA Laboratories GmbH,
Pasching, Austria). Mesencephalons were homogenized by
pipetting 30 times. Then, 5 ml Leibovitz L-15 medium
was added and the solution was left for 10 minutes to re-
move cell debris. Next, 5 ml was removed into a new tube,
centrifuged for 5 min at 300 g and the supernatant was
then resuspended in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS), 1% streptomycin/penicillin and 1% L-glutamine (all
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were seeded on polyethyleneimine-coated plates, culti-
vated at 37°C in a humidified atmosphere of 5% CO2,
and after 7 days, 5 ng/ml granulocyte-macrophage
colony-stimulating factor (Roche, Basel, Switzerland)
was added to increase the yield of microglia. After 15
to 19 days in culture, cells were subplated and used for
further experiments. For experiments, cell treatments
were performed 24 hours after seeding. More than 95%
of cells obtained were microglia as quantified by
CD11b FACS analysis.
BV-2 cells (a kind gift of Jens Neumann, Magdeburg,
Germany) were cultivated in DMEM supplemented
with 10% FBS, 1% penicillin/streptomycin and 1%
L-glutamine.
Measurement of TNF-α, IL-6 and IL-1β
Before cell treatment, media was changed to serum-free
media. Primary microglial cells were treated with 0.1 μg/
ml LPS or 10 μM Aβ1-42 and 2 or 4 mg/ml A1AT. After
24 hours, the concentration of the pro-inflammatory
cytokines TNF-α and IL-6 was measured in cell culture
supernatants using the Duoset Enzyme-linked immuno-
sorbent assay (ELISA) system (R&D, Minneapolis, MN,
USA) according to the manufacturer’s protocol. Super-
natants of cells treated with LPS and/or A1AT were also
subjected to an IL-1β ELISA (R&D, Minneapolis, MN,
USA). The absorbance was measured at 450 nm using a
plate reader (ELISA-Reader Infinite™ 200series, Tecan,
Crailsheim, Germany).
Measurement of nitric oxide
Accumulated nitrite, a stable oxidation product of nitric
oxide (NO), was measured using Griess reagents [21].
For this measurement, 50 μl of primary microglial cell
supernatants was transferred to a 96-well microtiter
plate, and 50 μl of solution 1 (1% sulfanilamide in 5%
phosphoric acid) was added. After 10 minutes incuba-
tion in the dark, 50 μl of solution 2 (0.1% naphthylethy-
lenediamine dihydrochloride) was added and incubated
for 10 more minutes in the dark. The absorbance was
measured at 550 nm using a plate reader (ELISA-Reader
Infinite™ 200series, Tecan, Crailsheim, Germany).
Cell lysis and western blot
Media was changed to serum-free media, and primary
microglial cells were treated for the indicated times,
washed twice with ice-cold phosphate-buffered saline
and lysed for 5 minutes with M-Per lysis buffer (Thermo
Scientific, Rockford, IL, USA) containing protease inhibi-
tors and phosphatase inhibitors (Roche, Basel, Switzerland).
Cells were harvested with a cell scraper and pelleted for
10 minutes at 14,000 rpm. Supernatants were transferred to
a new tube, and protein concentration was determinedusing NanoDrop (Peqlab, Erlangen, Germany). Next, 10 μg
of total protein was separated by 4 to 12% sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred onto nitrocellulose membranes. Mem-
branes were blocked for one hour at room temperature and
incubated with the appropriate primary antibody solution
for phospho-p38 (1:4,000), phospho p44/42 (1:4,000), phos-
pho JNK (1:4,000), phospho CREB (1:500), A1AT (1:2,000),
Aβ (1:2,000), GAPDH (1:5,000) or Vinculin (1:5,000) at 4°C
over night. Primary antibody was detected using a species-
specific secondary antibody. Membranes were incubated
with SuperSignalTM West Dura Extended Duration Sub-
strate (Thermo Scientific, Rockford, IL, USA) and exposed
to an autoradiographic film (Thermo Scientific, Rockford,
IL, USA). Band intensity levels were measured by GS-800™
calibrated densitometer (Bio-Rad, Hercules, CA, USA).
Intracellular calcium measurements with Fluo-4
To assess intracellular calcium levels 1.5 × 104 BV-2 cells
were seeded in a 96-well black plate, washed with Hank’s
buffered salt solution (HBSS) and loaded with the calcium
indicator Fluo-4 (5 μM) for 30 minutes at 37°C. The dye
was removed, cells were kept in HBSS and baseline cal-
cium levels for each well were assigned. The fluorescence
of each well was determined with an automated FLUOstar
Optima reader (BMG Labtechnologies GmbH, Offenburg,
Germany) using an excitation wavelength of 485 nm and
an emission wavelength of 520 nm.
To measure the effect of A1AT on intracellular cal-
cium levels, we treated cells with 0.1 μg/ml LPS and/or
2 and 4 mg/ml A1AT and fluorescence was measured
every 60 seconds for a time course of 200 minutes.
Calpain activity assay
To measure the calpain activity of primary microglial
cells, cells were seeded in a 24-well plate and media was
changed to serum-free media. Cells were treated with
0.5, 2 and 4 mg/ml A1AT for 24 hours and subjected to
a calpain activity assay (Abcam, Cambridge, UK). The
assay was performed according to the manufacturer’s
protocol.
Cell viability assessment with MTT reduction assay
Cell viability of Aβ1-42 oligomer-treated primary microglial
cells and A1AT co-treated cells was measured using a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) reduction assay. Media was changed to
serum-free media, and cells were treated with Aβ1-42
oligomers (2 μM) and A1AT (0.5, 2 and 4 mg/ml) for
24 hours. Culture medium was changed to fresh
medium containing 0.5 mg/ml MTT and incubated for
one hour at 37°C in a humidified atmosphere of 5%
CO2. Medium was removed and cells were lysed with
dimethyl sulfoxide (AppliChem, Darmstadt, Germany).
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(ELISA-Reader Infinite™ 200series, Tecan, Crailsheim,
Germany). Absorption values were normalized to untreated
cells.Statistical analysis
All results are presented as the mean ± standard devi-
ation of the mean. Differences between groups were
evaluated for statistical significance using one-way ana-
lysis of variance (ANOVA) with Bonferroni post-hoc test.
Data analysis was aided by XL Toolbox add-in for Excel,
version 6.52 (xltoolbox.sourceforge.net).
For all statistical comparisons, the following defini-
tions were used: (* = P value ≤ 0.05, ** = P value ≤ 0.01,



























































Figure 1 α1-antitrypsin (A1AT) reduces lipopolysaccharide (LPS)-induc
supernatants of LPS and/or A1AT co-treated cells were subjected to ELISA
microglial cells were treated with 0.1 μg/ml LPS and/or 2 and 4 mg/ml A1A
levels. Values are given in ng/ml. Means and standard deviations of the me
**P value ≤ 0.01, n.s., not significant). D. Nitric oxide (NO) was measured in
given in μM. Means and standard deviations of the mean of three indepenResults
α1-antitrypsin has an anti-inflammatory effect on
lipopolysaccharide-treated primary microglial cells
Primary microglial cells were treated for 24 hours with
0.1 μg/ml LPS and/or 2 and 4 mg/ml A1AT. Co-treatment
with 4 mg/ml A1AT led to a two- to threefold reduction of
TNF-α (P = 0.003), IL-6 (P = 0.002), IL-1β (P = 0.04) and
NO levels (P = 0.006) in primary microglial cells. The lower
dose of 2 mg/ml reduced TNF-α (P = 0.04), IL-6 (P = 0.02)
and NO (P = 0.04) levels significantly (Figure 1A, B +D),
whereas there was no effect on IL-1β (P = 0.16; Figure 1C).
A1ATalone did not show any immunogenicity.
Anti-inflammatory effect is not mediated via MAPK or PKA
It is well established that pro-inflammatory effects in im-

























































ed release of pro-inflammatory mediators. A-C. Cell culture
to detect the levels of pro-inflammatory cytokines. Therefore, primary
T for 24 hours, followed by quantification of TNF-α, IL-6, and IL-1β
an of three independent experiments are shown (*P value ≤ 0.05,
the same cell culture supernatants using Griess reagents. Values are
dent experiments are shown (*P value ≤ 0.05, **P value ≤ 0.01).
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NF-κB. To investigate the correlation of A1AT with
these classic inflammatory stress pathways, we analyzed
the phosphorylation state of p38, p44/42 and SAPK/JNK
upon treatment with 0.1 μg/ml LPS and A1AT after
20 minutes (Figure 2A). We saw a very slight negative
correlation of 4 mg/ml A1AT on LPS-induced phos-
phorylation of p44/42 (P = 0.04/0.002) and a slight posi-
tive correlation in the phosphorylation state of JNK p46
with 2 mg/ml A1AT (P = 0.04); Figure 2B). HoweverFigure 2 α1-antitrypsin (A1AT)’s reduction of pro-inflammatory media
the phosphorylation state of the MAPKs p38, p44/42 and JNK upon co-trea
μg/ml lipopolysaccharide (LPS) and 2 and 4 mg/ml A1AT for 20 minutes, a
Antibodies against phospho-p38, phospho-p44/42 and phospho-JNK were
blot out of three is shown. B. Band intensities of phosphorylated MAPK we
LPS-treated cells were set to 1. Means and standard deviations of the mean
C. To detect the effect of A1AT on the phosphorylation state of CREB, cells
treated with 4 mg/ml A1AT for 15 minutes or co-treated with 0.1 μg/ml LP
western blotting, and phospho-CREB was detected with a monoclonal anti
western blot out of three is shown. D. To measure the impact on the relea
different concentrations of H89 and then treated with 0.1 μg/ml LPS and/o
of primary microglial cells were quantified with ELISA. Results were normal
of three independent experiments are shown.there was no change in the phosphorylation state of p38
with any A1AT co-treatment and no correlation with
phospho p44/42 with 2 mg/ml A1AT co-treatment, a
concentration that showed reductive effects on pro-
inflammatory cytokines.
It has previously been reported that A1AT exerts its
anti-inflammatory effect via activation of PKA [11], indi-
cating an effect through the PKA/CREB pathway. Here,
we detected increased phospho-CREB levels upon micro-
glia treatment with 4 mg/ml A1AT and investigatedtors is independent of MAPK and PKA activation. A. To detect
tment with A1AT, primary microglial cells were incubated with 0.1
nd cell lysates of the treated cells were subjected to western blotting.
used. GAPDH served as a loading control. One representative western
re measured by a densitometer and normalized with that of GAPDH.
of three western blots are shown (*P value ≤ 0.05, **P value ≤ 0.01)
were pretreated with the PKA inhibitor H89 for 30 minutes and then
S and 4 mg/ml A1AT for 15 minutes. Cell lysates were subjected to
body. Vinculin was used as a loading control. One representative
se of the pro-inflammatory cytokine TNF-α, cells were pretreated with
r 2 mg/ml A1AT for 24 hours. TNF-α levels in cell culture supernatants
ized to LPS-treated cells. Means and standard deviations of the mean
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concentrations of the PKA-inhibitor H89 (1 to 30 μM). In-
deed, we detected an antagonistic effect of H89 on the
phosphorylation state of CREB (Figure 2C). However, the
phosphorylation state of CREB was also increased in LPS
and/or A1AT treated cells (Figure 2C). We further tested
the effect of H89 on the anti-inflammatory effect of 2 mg/
ml A1AT on LPS-treated cells. As shown in Figure 2D,
the release of the pro-inflammatory cytokine TNF-α after
LPS treatment could not be restored by different concen-
trations of H89 (1 to 10 μM). H89 treatment in the afore-
mentioned concentrations had no effect on cytokine levels
(data not shown).α1-antitrypsin reduces intracellular calcium-levels in BV-2
microglial cells
Calcium plays an important role in the activation of
microglial cells, is required for calpain activation and is
known to be enhanced in human AD brains [17,18].
Since we did not observe a strong regulative effect of
A1AT on MAPK and the regulation of PKA does not
seem to be responsible for the anti-inflammatory effect
of A1AT, we investigated the change of intracellular
calcium levels upon treatment with 0.1 μg/ml LPS and/
or different concentrations of A1AT with the calcium
fluorescent marker Fluo-4. For these experiments, we
used BV-2 microglial cells because primary microglial
cells change their shape dramatically after LPS treat-
ment, which might lead to a misinterpretation of the
results as Fluo-4 is a nonratiometric dye. Both con-
centrations applied here, 4 mg/ml A1AT as well as
2 mg/ml A1AT, reduced the rise of intracellular cal-
cium over time by approximately 25% (LPS + 4 mg/
ml: P = 0.0001, LPS + 2 mg/ml: P = 0.0002; Figure 3A,
B). A1AT treatment alone also reduces intracellular
calcium levels (4 mg/ml: P = 0.00004, 2 mg/ml: P = 0.02;
Figure 3B).α1-antitrypsin reduces calpain activity in primary
microglial cells
Al-Omari and colleagues showed an inhibitory role for
A1AT on calpain activity in neutrophil granulocytes
[16]. To investigate the effect of A1AT on calpain ac-
tivity in primary microglial cells, we treated cells for
24 hours with 0.5, 2 and 4 mg/ml A1AT and subjected
them to a calpain activity assay. A1AT reduced calpain
activity in a dose-dependent manner (Figure 3C). By
applying the highest concentration A1AT of 4 mg/ml,
calpain activity could be reduced by 59% (P = 0.002).
Also, 2 mg/ml A1AT reduced calpain activity by 47%
(P = 0.002) and 0.5 mg/ml A1AT reduced calpain activ-
ity by 34% (P = 0.03). Treatment with bovine serumalbumin using the same concentrations had no effect
on calpain activity (data not shown).
α1-antitrypsin has an anti-inflammatory effect on Aβ
oligomer-treated primary microglial cells
We were able to show an inhibitory effect of A1AT on
cytokines in microglial cells upon LPS treatment. In AD
it is assumed that Aβ oligomers induce the release of
pro-inflammatory cytokines in microglial cells [2]. Here,
we addressed the effect of A1AT on Aβ-induced inflam-
mation in primary microglial cells. Therefore, cells
were treated with 10 μM Aβ1-42 oligomers and co-
treated with 4 mg/ml A1AT. The co-treatment with
A1AT led to a significant reduction of TNF-α (P = 0.0008)
and IL-6 (P = 0.03) levels (Figure 4A, B). The baseline con-
centration of untreated cells was 17 pg/ml for TNF-α and
12 pg/ml for IL-6.
α1-antitrypsin treatment reduces Aβ oligomer-induced
cytotoxicity in primary microglial cells
To detect the effect of A1AT on cell viability of Aβ1-42
oligomer-treated primary microglial cells, we treated
cells with 2 μM Aβ1-42 oligomers and different concen-
trations of A1AT for 24 hours and subjected them to an
MTT assay. Aβ1-42 oligomers reduced the viability to
48%. Co-treatment with different concentrations of
A1AT exerted a positive effect on the cell viability in a
dose-dependent manner (Figure 5A). With the highest
concentration of A1AT, 4 mg/ml, cell viability was only
reduced to 65% (P = 0.002), and with 2 mg/ml, cell via-
bility was reduced to 60% (P = 0.0008). At 0.5 mg/ml
A1AT, the lowest dose, the viability of the Aβ oligomer-
treated cells did not improve (P = 0.28). To exclude un-
specific protein effects, we used the same concentrations
of bovine serum albumin, which had no effect on the
cell viability of Aβ1-42-treated cells (data not shown).
α1-antitrypsin has no impact on the oligomerization
process of Aβ
It has been previously reported that α1-antichymotrypsin,
a multifunctional glycoprotein of the serpin family [22],
and A1AT show inhibitory effects on the formation of fi-
brils and associated toxicity using Aβ25-35 and physio-
logical concentrations of α1-antichymotrypsin and
A1AT [23]. To investigate the effect of A1AT on the
oligomerization process of Aβ1-42, we performed west-
ern blot analysis using partly non-reducing conditions
and detected Aβ with the monoclonal antibody 6E10.
We further tested two different experimental setups. In
the first experimental design we oligomerized Aβ1-42 in
the presence of 0.2 and 2 mg/ml A1AT. In the second
experimental design, we added 0.2 and 2 mg/ml A1AT
after the oligomerization process and incubated the so-









































































Figure 3 α1-antitrypsin (A1AT) reduces intracellular calcium levels and calpain activity in microglial cells. To detect intracellular calcium
levels, BV-2 microglial cells were loaded with Fluo-4 and baseline calcium levels for each well were measured and subtracted from the values.
Cells were treated with 0.1 μg/ml lipopolysaccharide (LPS) and/or 2 and 4 mg/ml A1AT, and the course of intracellular calcium was measured
over 200 minutes. RFU (relative fluorescence units) were normalized to time point zero. A shows the course of the values for LPS and LPS +
4 mg/ml A1AT co-treated cells. One representative experiment out of three is shown. B shows the mean values and standard deviations of the
mean of the RFU of six wells after 100 minutes for LPS and/or A1AT-treated cells (***P value≤ 0.001). C. Calpain activity was detected 24 hours
after A1AT treatment with different concentrations of A1AT by using a calpain activity assay. Calpain activity of untreated cells was referred to as
100% activity. Means and standard deviations of the mean of three independent experiments are shown (*P value ≤ 0.05, **P value≤ 0.01).
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blot analysis. No differences in the oligomerization
process could be detected in any of the two conditions
(Figure 5B). Thus, the benefit of A1AT proteins on
Aβ1-42 toxicity is not attributed to an effect of A1AT
on the aggregation process of Aβ1-42.
α1-antitrypsin has an inhibitory effect on Aβ phagocytosis
The influence of A1AT on microglial phagocytosis of
Aβ1-42 oligomers was assessed by western blot analysis.
Therefore, primary microglial cells were treated with
2 μM Aβ1-42 oligomers and different concentrations of
A1AT (0.1 to 4 mg/ml) for three hours. Cell lysates weresubjected to western blot analysis and phagocytosed Aβ
was detected with the monoclonal anti-Aβ antibody
6E10 (Figure 5C). Co-treatment with A1AT led to a
strong inhibition of Aβ1-42 uptake, whereas different
concentrations of Aβ1-42 had no effect on the uptake of
A1AT (data not shown); thus we can exclude a competi-
tive effect.
Discussion
Compelling evidence suggests that activation of glia and
overexpression of glial cytokines are early events in the
pathogenesis of AD [24-26]. Toxic Aβ oligomers induce
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Figure 4 α1-antitrypsin (A1AT) reduces Aβ-induced release of TNF-α. ELISA measurements were performed to detect the amount of the
pro-inflammatory cytokines TNF-α (A) and IL-6 (B) in supernatants of Aβ1-42 oligomer and/or A1AT co-treated primary microglial cells 24 hours after
treatment. Results were normalized to basal cytokine levels of untreated cells. Experiments were performed at least three times independently.
Means and standard deviations of the mean of three independent experiments are shown (*P value ≤0.05, ***P value ≤0.001, n.s., not significant).
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inflammatory role in the activation of human monocytes
as well as of lung epithelial cells [11,12]. We therefore
were interested in the effect of A1AT in microglial-
mediated neuroinflammation and investigated the effect
of A1AT on Aβ and LPS-induced cytokines, intracellular
calcium levels, calpain activity, Aβ toxicity, Aβ aggrega-
tion and Aβ phagocytosis in primary microglial or BV-2
microglial cells.
Indeed, we were able to show a reduction in inflamma-
tory markers upon co-treatment with A1AT in LPS- and
Aβ-treated primary microglial cells. The strong immune
reaction obtained with LPS in primary microglial cells
could be reduced dramatically with A1AT. In our study,
this suppression of immune reaction was shown by the
analysis of the secreted amount of TNF-α, IL-6, IL-1β
and NO.
The established, classic signaling pathways via the
phosphorylation of the MAPKs p38, p44/42 or JNK were
not involved here because A1AT co-treatment had no ef-
fect on the phosphorylation state of the aforementioned
MAPKs. As A1AT has been shown to raise intracellular
cAMP levels via PKA in monocytes [11], and PKA in
turn plays also a role in inflammatory signaling [4,29],
we investigated the effect of A1AT on cAMP/PKA/phos-
pho-CREB signaling. Interestingly A1AT enhances the
phosphorylation of CREB, which can be antagonized by
the PKA inhibitor H89. However, this antagonism is not
reflected in the cytokine levels. TNF-α-levels could not
be restored with the PKA inhibitor H89. An involvementof the non-canonical cAMP signaling pathway via EPAC
has also been excluded with specific inhibitors (data not
shown).
The inhibition of intracellular calcium levels may well
be the reason for the reduction in the pro-inflammatory
mediators that we observed in our study [6,7]. Indeed,
by using a fluorescent calcium indicator (Fluo-4), we
were able to observe a reduction in intracellular calcium
levels of BV-2 microglial cells upon administration of
A1AT over time. Reduced levels of intracellular calcium
might contribute to the reduction of pro-inflammatory
mediators in our study, but further experiments are
needed to prove this theory. However, as mentioned be-
fore, calpain is activated by calcium [17], and we also ob-
served an inhibition of calpain activity upon treatment
with A1AT. Thus, A1AT could inhibit calpain via a re-
duction of intracellular calcium levels.
Additional studies on calpain activity and inflamma-
tion demonstrated that IκB, the inhibitor of the tran-
scription factor NF-κB, might be a substrate of calpain
[19]. Therefore, high levels of activated calpain disinhibit
NF-κB from its translocation to the nucleus and induce
gene expression of several pro-inflammatory cytokines,
including TNF-α and IL-6. However, further studies are
necessary to elucidate whether this molecular mechan-
ism also occurs in microglial cells.
After having seen impressive anti-inflammatory effects
and elucidated the mechanisms of A1AT on microglial-
mediated neuroinflammation, we further analyzed the
effect of A1AT on the toxicity, oligomerization and
Figure 5 α1-antitrypsin (A1AT) treatment reduces Aβ oligomer-induced cytotoxicity on primary microglial cells. A. Primary microglial
cells were treated with 2 μM Aβ1-42 oligomers and/or different concentrations of A1AT for 24 hours. An MTT-assay was performed to detect
the cell viability. Viability of untreated cells was referred to as 100% viability. Means and standard deviations of the mean of three independent
experiments are shown (**P value≤ 0.01, ***P value≤ 0.001, n.s., not significant). B. 58 μM Aβ preparations were oligomerized and the effect of
A1AT on the oligomerization process was assessed by western blotting with the monoclonal Aβ antibody 6E10. One representative western
blot out of three is shown. C. Uptake of Aβ1-42 oligomers under the influence of different concentrations of A1AT was investigated by western
blotting. Cells were treated with 2 μM Aβ and different concentrations of A1AT (4 mg/ml to 0.1 mg/ml) for three hours. We used the monoclonal
antibody 6E10 to detect Aβ and a polyclonal antibody to detect A1AT in cell lysates. GAPDH was used as loading control. One representative
western blot out of three is shown.
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dependent effect of A1AT on the viability of Aβ1-42
oligomer-treated primary microglial cells. Interestingly,
the lowest concentration of 0.5 mg/ml A1AT, which is
consistent with the serum A1AT concentration of A1AT
deficiency patients [30], had no protective effect. To dis-
tinguish between an extracellular or intracellular effect, we
checked the oligomerization state upon co-incubation
with A1AT and a possible influence of A1AT on the
oligomerization state after the oligomerization process, re-
spectively. No change in the oligomerization state couldbe observed in any of these experimental conditions. This
finding is in contrast to the study of Giunta et al., who
could show a small effect of A1AT on the fibrillation of
Aβ25-35 and a protective effect on the toxicity of Aβ25-35 in
a human red blood cell lysis model [23]. The observed re-
duction in calpain activity upon A1AT treatment might
account for the increased cell survival: enhanced calpain
activity is known to induce cell death [31].
A key feature of microglial cells is their capability of
phagocytosis, which supports brain homoeostasis by de-
grading cellular debris and also potentially neurotoxic
Gold et al. Journal of Neuroinflammation 2014, 11:165 Page 10 of 11
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cells can be observed in AD and is interpreted as one
pathological hallmark of the disease [32]. Here, we could
observe a decreased uptake of Aβ by microglial cells fol-
lowing incubation with A1AT. This result is in line with
previous findings, that calpain activation is an important
step to induce phagocytosis by monocytes [33]. Blocking
calpain activation by A1AT, as shown in this study,
should therefore result in a decreased capability of
phagocytosis. Of course, this is an undesired effect and
further experiments are needed to consider the positive
effects of A1AT regarding cytokines and toxicity versus
the negative effect on Aβ phagocytosis. An effect of
A1AT on the expression of Aβ degrading enzymes in
this experimental setting is not very likely due to the
short incubation time of only three hours.Conclusions
This in vitro study of the effect of A1AT on microglial
cells shows a protective and anti-inflammatory effect on
microglial cells. Besides the positive effect on the viabil-
ity of Aβ-treated cells, A1AT also reduces the release of
pro-inflammatory mediators. We assume that both ef-
fects are mediated via inhibitory effects on intracellular
calcium levels and calpain activation, yet the particular
effectors upstream of this inhibition still have to be iden-
tified and are subject of further studies. The inhibition
of Aβ-induced microglial cytotoxicity as well as the re-
lease of pro-inflammatory cytokines by A1AT can be
rated as beneficial to slow down neurodegenerative pro-
cesses in AD. However, we could also observe a decreased
ability to take up neurotoxic Aβ by microglial cells follow-
ing incubation with A1AT, which may be seen as an
unsolicited effect regarding immune-modulatory effects of
the substance. Further studies are needed to elucidate the
effects of A1AT in neurodegenerative processes - espe-
cially in context with neuronal cells. These findings
support the importance of the role of A1AT in
Alzheimer-associated neuroinflammation and the po-
tential of A1AT to transfer this knowledge for further
investigation in transgenic AD animals.
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